Literature DB >> 32500934

Treatment of bullous pemphigoid in Chinese patients with Tripterygium wilfordii Hook F.

Xiao-Lei Ge1,2, Si-Zhe Li1, Xinxing Jin1, Hong-Zhong Jin1, Ya-Gang Zuo1.   

Abstract

Tripterygium wilfordii Hook F (TwHF) is a traditional Chinese herb used in many medicinal applications, but the treatment of bullous pemphigoid (BP) with TwHF has never been reported. The aim of this study was to evaluate the efficacy and safety of TwHF in BP patients. A retrospective study was performed from January 2015 to September 2019 in the Department of Dermatology, Peking Union Medical College Hospital. A total of 10 patients with mild to moderate BP and treated with TwHF were enrolled in the study with 10 mild or moderate BP patients treated with systemic glucocorticoid randomly selected as controls. In the TwHF group, a major response was seen in seven patients, a minor response in one and no response was seen in two patients. In the glucocorticoid group, a major response was seen in nine patients and a minor response in one patient. Two patients experienced treatment failure. The time to disease control in the TwHF group (34 ± 11 days) was longer as compared to the glucocorticoid group (18 ± 8 days, P < .05). Ten patients relapsed during the follow-up period. The adverse events in the TwHF group were lower than those in the glucocorticoid group (13 vs 19). Low-dose TwHF may be effective and safe for treating mild and moderate BP.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Tripterygium wilfordii Hook F; bullous pemphigoid; efficacy; safety

Mesh:

Substances:

Year:  2020        PMID: 32500934     DOI: 10.1111/dth.13721

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Successful Treatment of Bullous Pemphigoid Lesions by Berberine Stamp Therapy: A Case Report and Literature Review.

Authors:  Linyan Cheng; Yi Wang; Hanzhi Lu; Wanjun Guo; Ge Yan; Jianyong Zhu; Dongjie Guo; Fulun Li
Journal:  Front Med (Lausanne)       Date:  2022-07-01

2.  Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Si-Hang Wang; Ya-Gang Zuo
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.